Establishing High-Probability Drug Targets
Selection of appropriate drug targets is the most critical factor for the success of a drug discovery program. PRISM BioLab focuses on selecting targets optimized for PepMetics® technology. Because the PepMetics® chemical space differs fundamentally from that of conventional small molecules, selecting suitable PPI targets requires specialized expertise.
By leveraging internal and external experience accumulated through multiple drug discovery programs, we evaluate potential targets from multiple perspectives.
Selection of Targets Best Suited to PepMetics®
PRISM BioLab selects targets based on whether PepMetics® technology can fully demonstrate its advantages. Target selection is guided by questions such as:
- Can hit compounds be generated using PepMetics® technology?
- Are appropriate evaluation systems available for PepMetics® compounds?
- Can pharmaceutical partners be identified once clinical candidates are generated?
- Does the target address unmet medical needs with sufficient commercial potential?
From the earliest stages of discovery, we carefully assess the entire path toward a drug product. Scientists from diverse disciplines continuously collaborate to identify targets with the highest probability of success.
SAB (Scientific Advisory Board)の紹介はこちら
Drug target selection requires objective and multifaceted evaluation beyond internal discussion. PRISM BioLab has established a Scientific Advisory Board (SAB) composed of external experts.
Meet SAB (Scientific Advisory Board)
Through critical discussions covering scientific validity, clinical relevance, development strategy, and business potential, the SAB supports the selection of superior drug targets. Incorporating insights from experienced third-party experts before initiating research programs represents a key strength of PRISM BioLab.
